Inhalable FSH to be evaluated

A new follicle stimulating hormone (FSH) from Syntonix Pharmaceuticals Inc. will undergo evaluation by Swiss firm Serano SA. The FSH:Fc SynFusion product is aimed at providing long-acting FSH therapy for the treatment of infertility. The chief advantage of the new product is that it can be inhaled and dosed less frequently than the hormones currently used which require daily injections.

Patients who are confident enough to administer daily injections themselves are not terribly inconvenienced by the current method, but they do experience varying degrees of discomfort. Other patients make a trip to the doctor or a nursing station to receive daily injections, which is a major inconvenience during the IVF protocol. If this inhalable FSH is successfully developed then IVF treatment will become even more routine.